SPRY3

Across TCGA pan-cancer cohorts, SPRY3 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SPRY3’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SPRY3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPRY3 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

LIHC, THCA, and UCEC are the cancer types where SPRY3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPRY3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.252	<.001	7	view →
THCA	All	All	−0.186	<.001	7	view →
UCEC	All	All	+0.770	<.001	6	view →
BRCA	All	III,IV	−0.361	<.001	6	view →
LUSC	All	III,IV	−0.405	.013	3	view →
CHOL	All	All	+0.403	.003	3	view →
KIRP	Male	All	−0.219	.002	2	view →
PRAD	All	All	−0.197	.005	2	view →
COAD	Female	IV	+0.314	.010	1	view →
HNSC	Female	III,IV	+0.287	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SPRY3–LIHC

Open the LIHC breakdown →